NCT01123460已完成不适用
Measurement of Potential Biomarkers Predicting Erlotinib Response
ECOG-ACRIN Cancer Research Group0 个研究点目标入组 127 人开始时间: 2010年4月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 127
- 主要终点
- Baseline serum NGAL, MMP-9, NGAL/MMP-9 complex, and soluble E-cadherin levels as predictors of erlotinib hydrochloride response
研究概览
简要总结
RATIONALE: Studying samples of blood in the laboratory from patients receiving erlotinib hydrochloride may help doctors learn more about the effects of erlotinib hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.
PURPOSE: This research study is studying biomarkers predicting response in patients with non-small cell lung cancer previously treated with erlotinib hydrochloride.
详细描述
OBJECTIVES:
- To evaluate whether serum NGAL, MMP-9, NGAL/MMP-9 complex, and soluble E-cadherin can be utilized as biomarkers to predict response in patients with non-small cell lung cancer treated with erlotinib hydrochloride.
OUTLINE: Serum samples are analyzed for NGAL, MMP-9, NGAL/MMP-9, and soluble E-cadherin by ELISA and Luminex assays.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Baseline serum NGAL, MMP-9, NGAL/MMP-9 complex, and soluble E-cadherin levels as predictors of erlotinib hydrochloride response
时间窗: 1 month
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Serum marker analysis of Erlotinib treatment in previously treated Non-small cell lung cancer (NSCLC) patients with and without Epidermal Growth Factor Receptor (EGFR) mutation (additional study of CJLSG0903/0904)on-small cell lung cancerJPRN-UMIN000005754Central Japan Lung Study Group (CJLSG)83
已完成
不适用
Hormone Changes in Women With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Receiving ErlotinibAdvanced Nonsmall Cell Lung CancerNCT00602433Northwestern University10
已完成
不适用
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNCT00085280National Cancer Institute (NCI)129
终止
不适用
Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate CancerProstate CancerNCT03256630Genomic Health®, Inc.128
招募中
不适用
Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung CancerAdenocarcinoma of LungNode LungNCT05665504H. Lee Moffitt Cancer Center and Research Institute250